Donald Rao

USPTO Granted Patents = 21 (Patent Applications = 12)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 2.2

ph-index = 6

Forward Citations = 101(Granted Patents)

Company Filing History:

Baylor College of Medicine

patents

where one patent can have more than one assignee

Years Active: 2012-2019

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10253331 - Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine (2019-04-09),

2. 9914977 - Individualized cancer therapy (2018-03-13),

3. 9790518 - Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine (2017-10-17),

4. 9695422 - Furin-knockdown bi-functional RNA (2017-07-04),

5. 9683237 - Multiple targeted RNAI for the treatment of cancers (2017-06-20),

6. 9556431 - ShRNA molecules and methods of use thereof (2017-01-31),

7. 9528991 - Individualized cancer therapy (2016-12-27),

8. 9382589 - Individualized cancer therapy (2016-07-05),

9. 9353373 - [object Object] (2016-05-31),

10. 9290763 - Construction of bifunctional short hairpin RNA (2016-03-22),

11. 9157084 - Furin-knockdown bi-functional RNA (2015-10-13),

12. 9133459 - Therapeutic RNA interference technology targeted to the PDX-1 oncogene in PDX-1 expressing neuroendocrine tumors (2015-09-15),

13. 9132146 - Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine (2015-09-15),

14. 8916530 - Individualized cancer therapy (2014-12-23),

15. 8906874 - Bi-functional shRNA targeting Stathmin 1 and uses thereof (2014-12-09),

Title: Donald Rao: Innovator in Cancer Treatment

Introduction

Donald Rao is a prominent inventor based in Dallas, TX, recognized for his significant contributions in the field of cancer immunotherapy. With a remarkable total of 21 patents to his name, Rao has established himself as a pioneering figure in developing innovative medical treatments aimed at combating cancer.

Latest Patents

Rao's latest patents include groundbreaking advancements in cancer vaccines. One such invention is the "Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine." This vaccine is designed to genetically modify autologous cancer cells to enhance the immune response against tumors. By employing bi-functional shRNAs to knock down furin expression and augment tumor antigen presentation through GM-CSF expression, the vaccine attenuates the immunosuppressive effects of TGF-β, promising a more effective treatment for patients.

Another noteworthy patent is the "Individualized Cancer Therapy," which provides a method for treating cancer by analyzing both cancerous and normal tissue specimens to develop tailored therapeutic approaches. This innovative method consists of various intricate steps, including extracting proteins and RNA, profiling gene expressions, and designing RNA interference expression cassettes to modulate gene expression, ultimately helping to improve patient outcomes in cancer treatment.

Career Highlights

Throughout his illustrious career, Donald Rao has collaborated with reputable organizations, including Gradalis, Inc. and Strike Bio, Inc. His work in these companies has focused on translating scientific discoveries into viable cancer therapies, underscoring his commitment to advancing medical science in the fight against cancer.

Collaborations

Rao has collaborated with esteemed colleagues such as John J. Nemunaitis and Neil Senzer. Their synergy in research has led to the development of innovative approaches to cancer treatment, further contributing to the field and aiding in the creation of more personalized medical therapies.

Conclusion

Donald Rao's contributions to cancer research and treatment represent a significant advance in the field of medical innovation. With his impressive portfolio of patents and collaborative efforts with distinguished professionals, Rao continues to lead the charge in developing effective cancer therapies, promising a hopeful future for those facing this daunting illness.

This text is generated by artificial intelligence and may not be accurate.